🧬 BDNF Extraction Viewer

Извлечено: 997 / 997 (100.0%) Средняя confidence: 0.13
← Назад к списку

Artemisinin attenuates 3-nitropropionic acid-induced neurodegeneration via HMGB1/TLR4/NF-κB modulation in a rat model of huntington's disease.

PMID: 41865324 · DOI: 10.1007/s12272-026-01604-1 · Archives of pharmacal research, 2026 · Aya M Mustafa, Mustafa Mudhafar, Ali M Elgindy, Manar M Esmail, Ahmed M Atwa, Aya M Shaheen, Abdullah F Radwan, Nourhan
📄 Abstract

Huntington's disease (HD) is a progressive neurodegenerative disorder characterized by motor, cognitive, and behavioral impairments associated with striatal neuronal loss, for which effective symptom-attenuating therapies remain lacking. Artemisinin (ART), a natural sesquiterpene lactone with established antioxidant and anti-inflammatory actions, has recently gained attention as a potential neuroprotective agent. This study evaluated the therapeutic relevance of ART in a rat model of HD induced by 3-nitropropionic acid (3-NP). 3-NP administration caused severe behavioral deficits, including an 81.8% reduction in rearing and a 74.9% reduction in ambulation (p < 0.0001), a 63.7% decrease in novel object exploration, and a 53.5% decline in Morris water maze target quadrant time versus controls. Biochemically, 3-NP elevated HMGB1 (4.8-fold), TLR4 (6.8-fold), RIPK1 (6.4-fold), RIPK3 (5.2-fold), MLKL (5.5-fold), p38-MAPK (4.2-fold), NF-κB (2.1-fold), and TNF-α (4.5-fold), while reducing GSH (57.6%), Nrf2 (77.7%), Sig1R (86.2%), D2R (64%), XIAP (77.8%), BDNF (57.6%) and SDH (61.44%) (all p < 0.0001). Treatment with ART (100 mg/kg) markedly restored behavioral performance, increasing rearing and ambulation by 3.2- and 2.6-fold, novel object exploration by 2.4-fold, and target quadrant time by 1.7-fold compared to the 3-NP group. At the molecular level, ART reduced HMGB1 (69.2%), TLR4 (60.4%), RIPK1 (66.3%), RIPK3 (66.4%), MLKL (58%), and TNF-α (62.5%), while significantly restoring GSH (2.1-fold), Nrf2 (3.7-fold), Sig1R (5.2-fold), D2R (2.6-fold), XIAP (3.7-fold), BDNF (2.3-fold) and SDH (1.94-fold) relative to 3-NP-treated rats. Collectively, these results demonstrate that ART confers robust neuroprotection against 3-NP-induced HD-like pathology by attenuating oxidative stress, suppressing HMGB1/TLR4/NF-κB signaling, inhibiting necroptosis, and upregulating neuroprotective markers. These findings highlight ART not only as a neuroprotective agent but also as a promising symptom-attenuating therapeutic candidate for Huntington's disease and other neurodegenerative disorders driven by oxidative and inflammatory stress.

Confidence: 0.31 · 15 полей извлечено
Идентификация (6 полей)
Target
Artemisinin
1.00
Alt. target
ART
1.00
Protein family
—
0.00
Functional class
—
0.00
Subcellular loc.
—
0.00
Isoforms (metab/obesity)
—
0.00
Механизм действия (21 полей)
Mechanism
Artemisinin attenuates neurodegeneration by modulating HMGB1/TLR4/NF-κB signaling, inhibiting necroptosis, reducing oxidative stress, and upregulating neuroprotective markers.
0.95
Mutations (obesity/lean)
—
0.00
Activity (obesity)
—
0.00
Activity temporal
—
0.00
Energy balance
—
0.00
Appetite
—
0.00
Fat metabolism
—
0.00
Lipolysis
—
0.00
Thermogenesis
—
0.00
Muscle metabolism
—
0.00
Inflammation
Artemisinin reduces inflammation by suppressing HMGB1/TLR4/NF-κB signaling and decreasing TNF-α.
0.90
Glucose metabolism
—
0.00
AA metabolism
—
0.00
Hormonal pathways
—
0.00
Cell death
Artemisinin inhibits necroptosis by reducing RIPK1, RIPK3, and MLKL levels.
0.90
Adipocyte fibrosis
—
0.00
Upstream (biochem)
3-nitropropionic acid (3-NP) upregulates HMGB1, TLR4, RIPK1, RIPK3, MLKL, p38-MAPK, NF-κB, TNF-α; downregulates GSH, Nrf2, Sig1R, D2R, XIAP, BDNF, SDH.
0.90
Upstream (physiol)
—
0.00
Downstream (biochem)
Artemisinin reduces HMGB1, TLR4, RIPK1, RIPK3, MLKL, TNF-α; restores GSH, Nrf2, Sig1R, D2R, XIAP, BDNF, SDH.
0.90
Downstream (physiol)
Artemisinin improves behavioral performance (rearing, ambulation, novel object exploration, Morris water maze target quadrant time).
0.90
PTMs
—
0.00
Экспрессия (8 полей)
Tissue expression
—
0.00
In vitro
—
0.00
In vivo
Rat model of Huntington's disease induced by 3-nitropropionic acid (3-NP). Artemisinin (100 mg/kg) treatment restored behavioral performance and modulated molecular markers.
0.95
In silico
—
0.00
Genetic association
—
0.00
Ex vivo
—
0.00
Animal model
Rat model of Huntington's disease induced by 3-nitropropionic acid (3-NP)
0.95
Diet/model
3-nitropropionic acid (3-NP) induced Huntington's disease model
0.95
Клиника (11 полей)
Drug
Artemisinin
1.00
Indication
Huntington's disease
1.00
Patient subgroups
—
0.00
Safety concerns
—
0.00
Off-target
—
0.00
Trial stage
Preclinical (rat model)
1.00
Pharma competitors
—
0.00
AE severity
—
0.00
MOA weight loss
—
0.00
Endpoints
—
0.00
Approved
False
0.90